Original Article
Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure
N Engl J Med 2001; 344:1358-1365May 3, 2001
- Abstract
Background
The benefits of angiotensin-converting–enzyme inhibitors and beta-blockers may be smaller in black patients than in patients of other races, but it is unknown whether race influences the response to carvedilol in patients with chronic heart failure.
Methods
In the U.S. Carvedilol Heart Failure Trials Program, 217 black and 877 nonblack patients (in New York Heart Association class II, III, or IV and with a left ventricular ejection fraction of no more than 0.35) were randomly assigned to receive placebo or carvedilol (at doses of 6.25 to 50 mg twice daily) for up to 15 months. The effects of carvedilol on ejection fraction, clinical status, and major clinical events were retrospectively compared between black and nonblack patients.
Results
As compared with placebo, carvedilol lowered the risk of death from any cause or hospitalization for any reason by 48 percent in black patients and by 30 percent in nonblack patients. Carvedilol reduced the risk of worsening heart failure (heart failure leading to death, hospitalization, or a sustained increase in medication) by 54 percent in black patients and by 51 percent in nonblack patients. The ratios of the relative risks associated with carvedilol for these two outcome variables in black as compared with nonblack patients were 0.74 (95 percent confidence interval, 0.42 to 1.34) and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. Carvedilol also improved functional class, ejection fraction, and the patients' and physicians' global assessments in both the black patients and the nonblack patients. For all these measures of outcome and clinical status, carvedilol was superior to placebo within each racial cohort (P<0.05 in all analyses), and there was no significant interaction between race and treatment (P>0.05 in all analyses).
Conclusions
The benefit of carvedilol was apparent and of similar magnitude in both black and nonblack patients with heart failure.
Media in This Article
Figure 2
Effects of Carvedilol in Black Patients and Nonblack Patients, Expressed as Relative Risks (Carvedilol vs. Placebo) of Five Outcome Variables.Figure 1
Kaplan–Meier Analysis of Cumulative Rates of Survival without Hospitalization among the Black Patients (Panel A) and among the Nonblack Patients (Panel B).Article Activity
- Article
Heart failure is a substantial public health problem among black Americans. It is more common in the black population than in other populations in the United States, affecting approximately 3 percent of all black adults in this country.1,2 Symptoms of heart failure develop in blacks at an earlier age than they do in nonblacks,3-5 possibly because blacks are more likely to have hypertension and diabetes and to have ventricular hypertrophy and vascular injury than nonblacks.5-8 Once diagnosed, heart failure progresses more rapidly in black patients than in white patients, as evidenced by the higher risk of initial and repeated hospitalization and of death in the former group.3-5,9,10 These risks cannot be explained by the presence of documented coronary artery disease, which is less common in blacks than in nonblacks with heart failure.3,8,10
What factors may explain or contribute to the poor long-term outcome in black patients with heart failure? First, the greater susceptibility of black patients to sodium retention, myocardial hypertrophy, and vascular injury may accelerate the rate of progression of heart failure.6,7,11 Second, limited access to medical care among black patients may delay both the diagnosis of heart failure and the prescription and use of effective medications.12,13 Third, even if deficiencies in access to medical care are corrected, pharmacologic interventions may be less effective in preventing adverse clinical events in black patients than in white patients. With regard to both hypertension and heart failure, blacks appear to derive less benefit than nonblacks from the use of angiotensin-converting–enzyme inhibitors and beta-blockers.4,14-17 As a result, there is a need to identify drugs that can control the progression of heart failure in black patients.
We conducted a retrospective analysis of the influence of race on the response to carvedilol among patients with heart failure who were enrolled in the U.S. Carvedilol Heart Failure Trials Program.18 Unlike other beta-blockers, carvedilol also inhibits α1-adrenergic receptors and has antioxidant properties that may contribute to its actions in patients with heart failure.19
Methods
Patients
The U.S. Carvedilol Heart Failure Trials Program was a prospectively designed, stratified set of four concurrently conducted trials that were monitored by a single ethics committee. Details of the study design and main results have been previously published.20 Of the 1094 patients enrolled, 217 (20 percent) were black and 877 (80 percent) were of European, Asian, or Native American descent. All the patients had heart failure categorized as New York Heart Association (NYHA) class II, III, or IV and a left ventricular ejection fraction of no more than 0.35, despite conventional therapy with diuretics and usually with digoxin and an angiotensin-converting–enzyme inhibitor.
Study Design
Patients who tolerated open-label therapy with carvedilol (6.25 mg twice daily for two weeks) were randomly assigned to receive placebo or carvedilol (in a 1:1, 1:2, or 1:3 ratio, depending on the trial).20-23 The dose of study medication was to be increased (over a period of 4 to 6 weeks); therapy was then to be maintained at the highest tolerated dose of medication (6.25 to 50 mg of carvedilol or placebo twice daily), which was to be given in addition to conventional therapy, for up to 15 months. Doses of conventional medication were to remain constant during the double-blind treatment period.
During maintenance therapy, changes in the NYHA functional class and changes in the patients' and physicians' global assessments were recorded every month, and the left ventricular ejection fraction was measured by radionuclide ventriculography after 6 and 12 months (or at the end of the double-blind treatment period). All the patients were prospectively followed for the occurrence of death or hospitalization; these events were analyzed by a data and safety monitoring board, which combined the data from all four trials to monitor the safety of therapy. The study was stopped early by the data and safety monitoring board because of drug efficacy.
Statistical Analysis
Each of the four trials had different prespecified primary and secondary end points, as previously described.20-23 All the analyses in the current report included all the patients who underwent randomization, and all the analyses were stratified according to trial. All the events were assigned to the patient's original treatment group, whether or not the patient was receiving the study medication (according to the intention-to-treat principle). Data on deaths and hospitalizations were collected regardless of cause; hospitalizations were classified as for heart failure, for a cardiovascular reason (including heart failure), or for a noncardiovascular reason.
The risk of death and of hospitalization was assessed by analyzing the time to a first event, and the differences between treatment groups within each racial cohort were tested for significance with use of a stratified Cox proportional-hazards model. In the analysis of death, data from patients who underwent cardiac transplantation were censored at the time of transplantation. Analyses of hospitalization always included death as the worst possible outcome so as to avoid the problem of competing risks. The clinical progression of heart failure was prospectively defined as worsening heart failure leading to death, hospitalization, or a sustained increase in conventional medications for heart failure.20 For each variable, treatment effects within each racial cohort and possible interactions between race and treatment were evaluated with the Cox model. All P values are two-sided.
Continuous data are summarized as means ±SD. Differences between racial groups in prerandomization characteristics and in postrandomization measurements were evaluated for significance by means of a general linear model (for continuous variables) or by logistic regression (for categorical variables). The NYHA functional class and global assessments were classified as improved, unchanged, or worsened. In all the analyses, the last value obtained during the double-blind treatment period was used; patients for whom values at the planned time of assessment were missing because of death or withdrawal due to worsening heart failure were assigned the worst rank for the given variables. Possible interactions between race and treatment were evaluated by incorporating an interaction term in the Cox model.
Results
Base-Line Characteristics
The 217 black patients were younger, on average, than the 877 nonblack patients (P<0.001) and were more likely to have hypertension or a history of hypertension (P<0.001), but they were less likely to have ischemic heart disease than the nonblacks (P<0.001) (Table 1Table 1
Base-Line Characteristics of the Patients.). These differences in base-line characteristics are consistent with those reported in other studies.3-5 Of the 217 black patients, 90 were randomly assigned to receive placebo and 127 to receive carvedilol; of the 877 nonblack patients, 308 were randomly assigned to receive placebo and 569 to receive carvedilol. The base-line characteristics of the placebo and carvedilol groups were similar in both the black and nonblack cohorts (Table 1). After randomization, the maintenance doses of carvedilol reached similar levels in the black and nonblack cohorts (23±13 and 21±13 mg twice daily, respectively; P=0.38), and the duration of treatment was also similar (179±91 days for the black patients and 189±101 days for the nonblack patients, P=0.85).
Hemodynamic Variables
After adjustment for the changes in the placebo groups, both the black patients and the nonblack patients had significant increases in left ventricular ejection fraction at the end of the double-blind treatment period (P<0.001 in both cohorts) but minimal changes in systolic and diastolic blood pressure; the magnitude of these effects was similar in the two cohorts (Table 2Table 2
Response to Treatment with Placebo or Carvedilol in the Black and Nonblack Patients.). In contrast, the black patients had greater decreases in heart rate than the nonblack patients (P=0.03). The magnitudes of the differences between the cohorts, after adjustment for the different racial distributions among the protocols (and expressed as the difference between the value in the black cohort and the value in the nonblack cohort), were as follows: ejection fraction, 0.02 (95 percent confidence interval, –0.01 to 0.05); systolic blood pressure, –0.34 mm Hg (95 percent confidence interval, –5.21 to 4.54); diastolic blood pressure, 0.54 mm Hg (95 percent confidence interval, –2.80 to 3.88); and heart rate, –4.27 beats per minute (95 percent confidence interval, –8.09 to –0.45).Clinical Status
Patients assigned to receive carvedilol were more likely to have improvement and less likely to have deterioration in terms of NYHA functional class and their own and the physicians' global assessments than patients assigned to receive placebo, whether they were black (P=0.006, P=0.002, and P<0.001, respectively) or nonblack (P=0.02, P<0.001, and P<0.001, respectively) (Table 2). The ratios of the relative risks for these three symptom-related variables in black as compared with nonblack patients were 0.64 (95 percent confidence interval, 0.34 to 1.18), 0.56 (95 percent confidence interval, 0.30 to 1.04), and 0.65 (95 percent confidence interval, 0.35 to 1.22), respectively. None of the P values for the interaction between treatment and race with respect to these variables were significant (P=0.15, P=0.18, and P=0.06, respectively).
Risk of Death or Hospitalization
Black patients receiving placebo were more likely to die from any cause than nonblack patients (mortality, 8.9 percent vs. 7.5 percent); they were also more likely to be hospitalized for any reason than nonblack patients (31.1 percent vs. 25.3 percent). However, carvedilol reduced the risk of death from any cause and the combined risk of death from any cause or hospitalization to a similar degree in the two racial cohorts (Table 3Table 3
Risk of Major Clinical Events According to Treatment Group.). Specifically, carvedilol lowered the risk of death from any cause by 56 percent in blacks and 68 percent in nonblacks; decreased the risk of death from any cause or hospitalization for any reason by 48 percent in blacks and by 30 percent in nonblacks (Figure 1Figure 1Kaplan–Meier Analysis of Cumulative Rates of Survival without Hospitalization among the Black Patients (Panel A) and among the Nonblack Patients (Panel B).); reduced the risk of death from any cause or hospitalization for a cardiovascular reason by 32 percent in blacks and by 35 percent in nonblacks; lowered the risk of death from any cause or hospitalization for heart failure by 43 percent in blacks and by 49 percent in nonblacks; and decreased the risk of progression of heart failure by 54 percent in blacks and by 51 percent in nonblacks (Figure 2Figure 2Effects of Carvedilol in Black Patients and Nonblack Patients, Expressed as Relative Risks (Carvedilol vs. Placebo) of Five Outcome Variables.). The ratios of the relative risks of these five outcome variables in black as compared with nonblack patients were 1.38 (95 percent confidence interval, 0.39 to 4.67), 0.74 (95 percent confidence interval, 0.42 to 1.34), 1.05 (95 percent confidence interval, 0.54 to 2.04), 1.12 (95 percent confidence interval, 0.47 to 2.72), and 0.94 (95 percent confidence interval, 0.43 to 2.05), respectively. None of the P values for the interaction between treatment and race for these five outcome variables were significant (P=0.63, P=0.33, P=0.89, P=0.78, and P=0.88, respectively).For the two outcome variables associated with the highest event rates in the placebo group, the effect of carvedilol was statistically significant, even when the analysis was confined to black patients. Specifically, among black patients, carvedilol as compared with placebo reduced the combined risk of death from any cause or hospitalization for any reason by 48 percent (P=0.01) and lowered the risk of progression of heart failure by 54 percent (P=0.03).
Safety
During the two weeks of open-label therapy with carvedilol, the rates of withdrawal due to death or adverse reactions were similar among the black patients and the nonblack patients (5.1 percent and 6.8 percent, respectively). After randomization, the frequency of specific adverse events in the carvedilol group (after adjustment for the frequency of events in the placebo group) was also similar among the black patients and the nonblack patients, except that carvedilol produced hypotension (but not dizziness) more frequently in nonblacks than in blacks (P=0.02 for the interaction between race and treatment), possibly because of the lower base-line blood pressures in nonblack patients (Table 1). Most of the adverse events were mild or moderate in severity and resolved either spontaneously or after a reduction in the dose of the study medication. The proportion of patients who discontinued treatment because of an adverse event was lower in the carvedilol group than in the placebo group, whether patients were black (7 percent vs. 14 percent, P=0.06) or nonblack (8 percent vs. 12 percent, P=0.02). In addition, there was no difference in these proportions between the two racial cohorts.
Discussion
Previous studies have suggested that black patients with heart failure may derive less benefit than nonblack patients from drugs that prolong life and reduce the risk of hospitalization or that they may even have a detrimental response to such drugs.4,16,17 In the present retrospective analysis, however, race did not influence the response to carvedilol in patients with heart failure. Long-term treatment with carvedilol improved cardiac function, lessened symptoms, and reduced the risk of death and hospitalization to a similar degree in black patients and nonblack patients. Furthermore, the favorable effect of carvedilol on clinical status, NYHA functional class, left ventricular ejection fraction, the risk of the combined end point of death or hospitalization, and the progression of heart failure in black patients was significant in its own right. These findings suggest that the appropriate use of carvedilol may help to lessen the public health effects of heart failure in the black community.
The results of our analysis of the effects of carvedilol differ from those observed in previous studies of neurohormonal antagonists in patients with heart failure. In the Studies of Left Ventricular Dysfunction (SOLVD)16 and in the second Vasodilator–Heart Failure Trial (V-HeFT II),4 angiotensin-converting–enzyme inhibitors reduced the risk of death or hospitalization in white patients but not black patients. In the Beta-Blocker Evaluation of Survival Trial,17 the beta-blocker bucindolol reduced the risk of death or hospitalization among nonblack patients but was associated with a nonsignificant increase in the risk of a serious clinical event in black patients. In all three of these studies, a statistically significant or nearly significant interaction between treatment and race was observed. This pattern of response in patients with heart failure is strikingly similar to that seen in patients with hypertension — that is, the antihypertensive efficacy of both angiotensin-converting–enzyme inhibitors and beta-blockers is lower in black patients than in white patients.14,15 This racial difference has been attributed to the fact that neurohormonal systems may have a smaller role in the control of blood pressure in blacks than in whites.24-26
What might explain the favorable responses to carvedilol in the black patients evaluated in the present analyses? Unlike metoprolol and bisoprolol, carvedilol inhibits both β2- and α1-adrenergic receptors.19 Such actions are noteworthy, since blacks have greater responses to cardiac β2-adrenergic stimuli and peripheral α1-adrenergic stimuli than whites,27-30 particularly in states of potassium depletion.31 As a result, both β2- and α1-adrenergic blockade may be especially important in black patients, particularly those with heart failure, whose potassium balance may be disturbed by the concomitant use of diuretics. This hypothesis is supported by the observation in the present study that carvedilol was associated with a greater reduction in the heart rate in black patients than in nonblack patients and by the previous finding that the resistance of hypertension to beta-blockade in black patients can be overcome by the use of a beta-blocker with alpha-blocking properties.32 Combined alpha- and beta-blockade may also minimize the adverse effects of beta-blockade alone on blood lipids and insulin sensitivity,33,34 two important cofactors in the evolution of cardiovascular disease in black patients.6,35
Long-term therapy with carvedilol was well tolerated by the black patients in this study. The most worrisome adverse effect of beta-blockade in patients with heart failure — worsening heart failure — occurred with a similar frequency in the two racial cohorts. This finding may be surprising, since beta-blockers cause worsening heart failure primarily by reducing renal blood flow and sodium excretion,36,37 and since blacks are more likely to have impaired renal blood flow and to retain sodium than nonblacks.38,39 However, in the present study, black patients (like nonblack patients) who received carvedilol had a lower risk of progression of heart failure during treatment than those who received placebo. The finding that black patients were not at increased risk of heart failure may be related to the alpha-blocking actions of carvedilol.
The present analyses were not based on a prospectively designed trial in black patients, and randomization in the trials that were the source of the analyzed data was not stratified according to race; thus, it is possible that our findings are due to idiosyncrasies in our patient population or to chance. However, the black patients in our study differed from their nonblack counterparts in precisely the manner that would be predicted from earlier studies: they were younger (indicating an earlier onset of heart failure), were more likely to have hypertension, were less likely to have ischemic heart disease, and had higher rates of hospitalization than the nonblack patients.3-8 Nevertheless, our results differed from the results of earlier trials of angiotensin-converting–enzyme inhibitors and beta-blockers.3,4,17 In contrast to those trials, in which the benefits of treatment were found to be largely confined to the nonblack population, our study found the effects of carvedilol on the risk of major clinical events in black patients to be uniformly favorable. These analyses suggest that the effects of carvedilol in black patients may differ meaningfully from those of other beta-blockers — a hypothesis that requires confirmation by further prospective study.
Supported by grants from SmithKline Beecham Pharmaceuticals and Roche Laboratories.
Drs. Yancy, Fowler, Colucci, Gilbert, Bristow, and Packer have served as consultants to Glaxo SmithKline, and Drs. Lukas and Young are or have been employed by Glaxo SmithKline and are owners of stock in that company.
We are indebted to Sandra Lottes, Pharm.D., Tony Chen, Ph.D., Nedra Lexow, Ph.D., and Neil Shusterman, M.D., for technical assistance and support; and to Ele Emanuel and Kathleen Dougan for assistance in the preparation of the manuscript.
Source Information
From the University of Texas Southwestern Medical Center, Dallas (C.W.Y.); Stanford University School of Medicine, Palo Alto, Calif. (M.B.F.); Boston University School of Medicine, Boston (W.S.C.); the University of Utah School of Medicine, Salt Lake City (E.M.G.); the University of Colorado School of Medicine, Denver (M.R.B.); the University of Minnesota Medical School, Minneapolis (J.N.C.); Glaxo SmithKline, King of Prussia, Pa. (M.A.L., S.T.Y.); and Columbia University College of Physicians and Surgeons, New York (M.P.).
Address reprint requests to Dr. Yancy at the Division of Cardiology, CS7 102, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-9047, or at clyde.yancy@utsouthwestern.edu.
Other members of the U.S. Carvedilol Heart Failure Study Group are listed in the Appendix.
Appendix
The other principal investigators of the U.S. Carvedilol Heart Failure Study Group were as follows: Albuquerque, N.M. — Lovelace Scientific Resources: L. Kuo; Baltimore — Johns Hopkins University Hospital: E. Kasper and A.M. Feldman; Union Memorial Hospital: H. Meilman and D. Goldscher; and University of Maryland: S.S. Gottlieb; Beverly Hills, Calif. — Cardiovascular Research Institute of Southern California: R. Karlsburg; Boston — Boston City Hospital: R.H. Falk; Brigham and Women's Hospital: W. Carlson; Massachusetts General Hospital: G.W. Dec; and New England Medical Center: J.E. Udelson; Bronx, N.Y. — Albert Einstein College of Medicine: T.H. LeJemtel; Chapel Hill, N.C. — University of North Carolina: K. Adams; Cleveland — Cleveland Clinic: R. Hobbs; Columbus, Ohio — Ohio State University Hospital: R.J. Cody; Dallas — Veterans Affairs Medical Center: E. Eichhorn; East Meadow, N.Y. — Nassau County Medical Center: E. Brown and I. Freeman; Elmhurst, N.Y. — Elmhurst Hospital Center: N. Kantrowitz; Falls Church, Va. — Inova Health System: J. Kiernan, J. O'Brien, and P. Carson; Grosse Pointe, Mich. — Henry Ford Health System and Pierson Clinic: V. Kinhal; Houston — Baylor College of Medicine: J. Young; and University of Texas Medical School: G. Schroth and S.E. El Hafi; Jackson, Miss. — University of Mississippi Medical Center: J. O'Connell; Jacksonville, Fla. — University of Florida: A. Miller; Las Vegas — Heart Institute of Nevada: J.A. Bowers; Lincoln, Nebr. — Nebraska Heart Institute: S. Krueger; Los Angeles — University of Southern California School of Medicine: V. DeQuattro; Madison, Wis. — University of Wisconsin School of Medicine: P.S. Rahko; Memphis, Tenn. — University of Tennessee School of Medicine: K.B. Ramanathan; Miami — University of Miami: E. deMarchena; Mineola, N.Y. — Cardiovascular Medical Associates: M. Goodman; and Winthrop University Hospital: R. Steingart; Minneapolis — University of Minnesota Medical School: S. Kubo; Nashville — Vanderbilt University Medical Center: J.R. Wilson and T.K. Yeoh; New Haven, Conn. — Yale University School of Medicine: F. Lee; New York — Columbia–Presbyterian Medical Center: J. Sackner-Bernstein and G.W. Neuberg; Mount Sinai Medical Center: M. Kukin; and St. Luke's–Roosevelt Medical Center: M. Klapholz; Northport, N.Y. — Veterans Affairs Medical Center: G. Mallis; Oklahoma City — University of Oklahoma and Veterans Affairs Medical Center: U. Thadani; Park Ridge, Ill. — Lutheran General Hospital: R.P. Sorkin; Philadelphia — Temple University Hospital: I. Pina; Phoenix, Ariz. — Carl T. Hayden Veterans Affairs Medical Center: J.V. Felicetta; Pittsburgh — Presbyterian University Hospital: B. Uretsky and S. Murali; and Western Pennsylvania Hospital: A. Gradman; Portland, Oreg. — Oregon Health Sciences Center: R. Hershberger; Richmond, Va. — Medical College of Virginia: G.W. Vetrovec; Rochester, Minn. — Mayo Medical School: L.J. Olson; Rochester, N.Y. — University of Rochester Medical Center: C.S. Liang; San Diego, Calif. — Cardiology Associates Medical Group of East San Diego: L. Yellen; and Sharp Rees-Stealy Medical Center: H. Ingersoll; San Francisco — California Pacific Medical Center: S. Woodley; and Veterans Affairs Medical Center: B.M. Massie; Sellersville, Pa. — Buxmont Cardiology Associates: M. Greenspan; St. Louis — St. Louis University Medical Center: L.W. Miller, S.H. Jennison, A.J. Lonigro, and H. Stratman; Summit, N.J. — Overlook Hospital: J.J. Gregory; Torrance, Calif. — Harbor–UCLA Medical Center: K.A. Narahara; Tucson, Ariz. — University of Arizona Medical Center: S. Butman; Washington, D.C. — Georgetown University Hospital: D. Pearle; Winston-Salem, N.C. — Bowman Gray School of Medicine: F. Kahl; and Worcester, Mass. — University of Massachusetts Medical Center: L. Heller. Committee members were as follows: Executive Committee — M. Packer, M.R. Bristow, J.N. Cohn, W.S. Colucci, M.B. Fowler, and E.M. Gilbert; Data and Safety Monitoring Board — A.M. Katz (chair), T. Bashore, C.E. Davis, and P. Kowey; Biostatistics — J. Hosking and S.T. Young; and Study Operations and Monitoring — N.H. Shusterman, M.A. Lukas, A. Flagg, T. Holcslaw, and L.G. Parchman.
- References
References
1
Biostatistical fact sheet: African-Americans and cardiovascular diseases. Dallas: American Heart Association, 1999.
2
Data fact sheet: congestive heart failure in the United States: a new epidemic. Bethesda, Md.: National Heart, Lung, and Blood Institute, 1996.
3
Dries DL ,Exner DV ,Gersh BJ ,Cooper HA ,Carson PE ,Domanski MJ . Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999;340:609-616[Erratum, N Engl J Med 1999;341:298.]
Full Text | Web of Science | Medline4
Carson P ,Ziesche S ,Johnson G ,Cohn JN . Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail 1999;5:178-187
CrossRef | Medline5
Afzal A ,Ananthasubramaniam K ,Sharma N , et al. Racial differences in patients with heart failure. Clin Cardiol 1999;22:791-794
CrossRef | Web of Science | Medline6
Saunders E . Hypertension in minorities: blacks. Am J Hypertens 1995;8:115s-119s
CrossRef | Web of Science | Medline7
Mayet J ,Shahi M ,Foale RA ,Poulter NR ,Sever PS ,McG Thom SA . Racial differences in cardiac structure and function in essential hypertension. BMJ 1994;308:1011-1014
CrossRef | Web of Science | Medline8
Philbin EF ,DiSalvo TG . Influence of race and gender on care process, resource utilization, and hospital-based outcomes in congestive heart failure. Am J Cardiol 1998;82:76-81
CrossRef | Web of Science | Medline9
Ghali JK ,Cooper R ,Ford E . Trends in hospitalization rates for heart failure in the United States, 1973-1986: evidence for increasing population prevalence. Arch Intern Med 1990;150:769-773
CrossRef | Web of Science | Medline10
Alexander M ,Grumbach K ,Selby J ,Brown AF ,Washington E . Hospitalization for congestive heart failure: explaining racial differences. JAMA 1995;274:1037-1042
CrossRef | Web of Science | Medline11
Douglas JG ,Thibonnier M ,Wright JT . Essential hypertension: racial/ethnic differences in pathophysiology. J Assoc Acad Minor Phys 1996;7:16-21
Medline12
Haywood LJ . Hypertension in minority populations: access to care. Am J Med 1990;88:17S-20S
CrossRef | Web of Science | Medline13
Coughlin SS ,Myers L ,Michaels RK . What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, Dilated Cardiomyopathy Study. J Natl Med Assoc 1997;89:277-282
Web of Science | Medline14
Cubeddu LX ,Aranda J ,Singh B , et al. A comparison of verapamil and propranolol for the initial treatment of hypertension: racial differences in response. JAMA 1986;256:2214-2221
CrossRef | Web of Science | Medline15
Materson BJ ,Reda DJ ,Cushman WC , et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921[Erratum, N Engl J Med 1994;330:1689.]
Full Text | Web of Science | Medline16
Exner DV ,Dries DL ,Domanski MJ ,Cohn JN . Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001;344:1351-1357
Full Text | Web of Science | Medline17
Domanski MJ . Beta-blocker evaluation of survival trial (BEST). J Am Coll Cardiol 2000;35:Suppl A:202A-203A abstract.
Web of Science18
Packer M ,Bristow MR ,Cohn JN , et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355
Full Text | Web of Science | Medline19
Feuerstein G ,Yue TL ,Ma X ,Ruffolo RR . Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol. Prog Cardiovasc Dis 1998;41:Suppl 1:17-24
CrossRef | Web of Science | Medline20
Colucci WS ,Packer M ,Bristow MR , et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806
Web of Science | Medline21
Packer M ,Colucci WS ,Sackner-Bernstein JD , et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE Trial. Circulation 1996;94:2793-2799
Web of Science | Medline22
Bristow MR ,Gilbert EM ,Abraham WT , et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-2816
Web of Science | Medline23
Cohn JN ,Fowler MB ,Bristow MR , et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997;3:173-179
CrossRef | Medline24
Voors AW ,Berenson GS ,Dalfers ER ,Webber LS ,Shuler SE . Racial differences in blood pressure control. Science 1979;204:1091-1094
CrossRef | Web of Science | Medline25
Lang CC ,Stein CM ,He HB , et al. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. Hypertension 1997;30:157-162
Web of Science | Medline26
Pratt JH ,Manatunga AK ,Bowsher RR ,Henry DP . The interaction of norepinephrine excretion with blood pressure and race in children. J Hypertens 1992;10:93-96
CrossRef | Web of Science | Medline27
Duey WJ ,Bassett DR ,Walker AJ , et al. Cardiovascular and plasma catecholamine response to static exercise in normotensive blacks and whites. Ethn Health 1997;2:127-136
CrossRef | Medline28
Dimsdale JE ,Graham RM ,Ziegler MG ,Zusman RM ,Berry CC . Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. Hypertension 1987;10:564-569
Web of Science | Medline29
Sherwood A ,Hinderliter AL . Responsiveness to alpha- and beta-adrenergic receptor agonists: effect of race in borderline hypertensive compared to normotensive men. Am J Hypertens 1993;6:630-635
Web of Science | Medline30
Mills PJ ,Dimsdale JE ,Ziegler MG ,Nelesen RA . Racial differences in epinephrine and beta 2-adrenergic receptors. Hypertension 1995;25:88-91
Web of Science | Medline31
Sudhir K ,Forman A ,Yi SL , et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension 1997;29:1083-1090
Web of Science | Medline32
Flamenbaum W ,Weber MA ,McMahon FG ,Materson BJ ,Carr AA ,Poland M . Monotherapy with labetalol compared with propranolol: differential effects by race. J Clin Hypertens 1985;1:56-69
Medline33
Jacob S ,Rett K ,Wickmayr M ,Agrawal B ,Augustin HJ ,Dietze G-J . Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-494[Erratum, J Hypertens 1996;14:1382.]
CrossRef | Web of Science | Medline34
Giugliano MD ,Acampora R ,Marfella R , et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 1997;126:955-959
Web of Science | Medline35
He J ,Klag MJ ,Caballero B ,Appel LJ ,Charleston J ,Whelton PK . Plasma insulin levels and incidence of hypertension in African Americans and whites. Arch Intern Med 1999;159:498-503
CrossRef | Web of Science | Medline36
Gaffney TE ,Braunwald E . Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963;34:320-324
CrossRef | Web of Science | Medline37
Epstein SE ,Braunwald E . The effect of beta adrenergic blockade on patterns of urinary sodium excretion: studies in normal subjects and in patients with heart disease. Ann Intern Med 1966;65:20-27
Web of Science | Medline38
Luft FC ,Weinberger MH ,Grim CE ,Fineberg NS ,Miller JZ . Sodium sensitivity in normotensive human subjects. Ann Intern Med 1983;98:758-762
Web of Science | Medline39
Levy SB ,Talner LB ,Coel MN ,Holle R ,Stone RA . Renal vasculature in essential hypertension: racial differences. Ann Intern Med 1978;88:12-16
Web of Science | Medline
- Citing Articles (103)
Citing Articles
1
Lemuel A. Moyé. (2012) Rudiments of Subgroup Analyses. Progress in Cardiovascular Diseases 54:4, 338-342
CrossRef2
Nicholas B Norgard, Gina M Prescott. (2011) Future of personalized pharmacotherapy in chronic heart failure patients. Future Cardiology 7:3, 357-379
CrossRef3
Vesna Radovic. (2011) Use of beta blockers in various clinical states. Medicinski pregled 64:1-2, 55-60
CrossRef4
Roberto Antonicelli, Ilaria Mazzanti, Angela M. Abbatecola, Gianfranco Parati. (2010) Impact of Home Patient Telemonitoring on Use of β-Blockers in Congestive Heart Failure. Drugs & Aging 27:10, 801-805
CrossRef5
(2010) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 16:6, e169-e175
CrossRef6
Jonathan G. Howlett, Robert S. McKelvie, Jeannine Costigan, Anique Ducharme, Estrellita Estrella-Holder, Justin A. Ezekowitz, Nadia Giannetti, Haissam Haddad, George A. Heckman, Anthony M. Herd, Debra Isaac, Simon Kouz, Kori Leblanc, Peter Liu, Elizabeth Mann, Gordon W. Moe, Eileen O’Meara, Miroslav Rajda, Samuel Siu, Paul Stolee, Elizabeth Swiggum, Shelley Zeiroth. (2010) The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Canadian Journal of Cardiology 26:4, 185-202
CrossRef7
Gordon W Moe, Jack Tu. (2010) Heart failure in the ethnic minorities. Current Opinion in Cardiology 25:2, 124-130
CrossRef8
Ibrahim N. Mansour, Sirikarn Napan, M. Tarek Alahdab, Thomas D. Stamos. (2010) Carbohydrate Antigen 125 Predicts Long-Term Mortality in African American Patients With Acute Decompensated Heart Failure. Congestive Heart Failure 16:1, 15-20
CrossRef9
Sharon Cresci, Reagan J. Kelly, Thomas P. Cappola, Abhinav Diwan, Daniel Dries, Sharon L.R. Kardia, Gerald W. Dorn. (2009) Clinical and Genetic Modifiers of Long-Term Survival in Heart Failure. Journal of the American College of Cardiology 54:5, 432-444
CrossRef10
Haig Tcheurekdjian, Shannon M. Thyne, L Keoki Williams, Marc Via, Jose R. Rodriguez-Santana, William Rodriguez-Cintron, Pedro C. Avila, Esteban González Burchard. (2009) Augmentation of bronchodilator responsiveness by leukotriene modifiers in Puerto Rican and Mexican children. Annals of Allergy, Asthma & Immunology 102:6, 510-517
CrossRef11
Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
CrossRef12
Pawan D. Patel, Jose L. Velazquez, Rohit R. Arora. (2009) Endothelial dysfunction in African-Americans. International Journal of Cardiology 132:2, 157-172
CrossRef13
Philip A. Poole-Wilson. (2008) Global Differences in the Outcome of Heart Failure. Journal of the American College of Cardiology 52:20, 1649-1651
CrossRef14
Clyde W. Yancy. (2008) Race-based therapeutics. Current Hypertension Reports 10:4, 276-285
CrossRef15
Mori J. Krantz, Edward P. Havranek, Deborah K. Haynes, Inez Smith, Becki Bucher-Bartelson, Carlin S. Long. (2008) Inpatient Initiation of β-blockade Plus Nurse Management in Vulnerable Heart Failure Patients: A Randomized Study. Journal of Cardiac Failure 14:4, 303-309
CrossRef16
Gopal KR Soppa, Paul JR Barton, Cesare MN Terracciano, Magdi H Yacoub. (2008) Left ventricular assist device-induced molecular changes in the failing myocardium. Current Opinion in Cardiology 23:3, 206-218
CrossRef17
Tamara B. Horwich, Gregg C. Fonarow. (2008) Heart failure in African Americans: Earlier onset, different etiologies, and poorer prognosis. Current Cardiovascular Risk Reports 2:3, 198-202
CrossRef18
Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
CrossRef19
Ludovica Lorusso, Giovanni Boniolo. (2008) Clustering humans: on biological boundaries. Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences 39:1, 163-170
CrossRef20
Aaron S. Blom, Michael A. Acker. (2007) The Surgical Treatment of End-Stage Heart Failure. Current Problems in Cardiology 32:10, 553-599
CrossRef21
S. D. Naik, Ronald S. Freudenberger. (2007) Beta-blocker contraindications: Are there patients or situations where use is inappropriate?. Current Heart Failure Reports 4:2, 93-98
CrossRef22
Gautam R. Shroff, Anne L. Taylor, Monica Colvin-Adams. (2007) Race-related differences in heart failure therapies: Simply black and white or shades of grey?. Current Cardiology Reports 9:3, 178-181
CrossRef23
Clyde W. Yancy. (2007) Race-based therapeutics. Current Cardiovascular Risk Reports 1:2, 108-117
CrossRef24
Brent R. DeGeorge, Walter J. Koch. (2007) Beta blocker specificity: a building block toward personalized medicine. Journal of Clinical Investigation 117:1, 86-89
CrossRef25
Jalal K Ghali, S William Tam, Keith C Ferdinand, JoAnn Lindenfeld, Michael L Sabolinski, Anne L Taylor, Manuel Worcel, Charles L Curry, Jay N Cohn. (2007) Effects of ACE Inhibitors or β-Blockers in Patients Treated with the Fixed-Dose Combination of Isosorbide Dinitrate/Hydralazine in the African-American Heart Failure Trial. American Journal of Cardiovascular Drugs 7:5, 373-380
CrossRef26
William T. Abraham, Barry M. Massie, Mary Ann Lukas, Sandra R. Lottes, Jeanenne J. Nelson, Michael B. Fowler, Barry Greenberg, Edward M. Gilbert, Joseph A. Franciosa. (2007) Tolerability, Safety, and Efficacy of ?-Blockade in Black Patients With Heart Failure in the Community Setting: Insights From a Large Prospective ?-Blocker Registry. Congestive Heart Failure 13:1, 16-21
CrossRef27
Melvin R. Echols, G. Michael Felker, Kevin L. Thomas, Karen S. Pieper, Jyotsna Garg, Michael S. Cuffe, Mihai Gheorghiade, Robert M. Califf, Christopher M. O'Connor. (2006) Racial Differences in the Characteristics of Patients Admitted for Acute Decompensated Heart Failure and Their Relation to Outcomes: Results From the OPTIME-CHF Trial. Journal of Cardiac Failure 12:9, 684-688
CrossRef28
Joseph A Franciosa. (2006) Fixed combination isosorbide dinitrate–hydralazine for nitric-oxide-enhancing therapy in heart failure. Expert Opinion on Pharmacotherapy 7:18, 2521-2531
CrossRef29
Kumudha Ramasubbu, Biykem Bozkurt, Douglas L Mann. (2006) Mechanisms of idiopathic dilated cardiomyopathies. Current Opinion in Organ Transplantation 11:5, 553-559
CrossRef30
Nicolas W Shammas. 2006. Congestive Heart Failure: Epidemiology, Pathophysiology, and Current Therapies. , 525-544.
CrossRef31
RL Bowen, J Stebbing, LJ Jones. (2006) A review of the ethnic differences in breast cancer. Pharmacogenomics 7:6, 935-942
CrossRef32
Larisa H. Cavallari, Vicki L. Groo, Kathryn M. Momary, Deidra Fontana, Marlos A.G. Viana, Paul Vaitkus. (2006) Racial Differences in Potassium Response to Spironolactone in Heart Failure. Congestive Heart Failure 12:4, 200-205
CrossRef33
Albert Yuh-Jer Shen, Somjot S Brar, Steven S Khan, Dean A Kujubu. (2006) Association of race, heart failure and chronic kidney disease. Future Cardiology 2:4, 441-454
CrossRef34
Judy W.M. Cheng. (2006) A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clinical Therapeutics 28:5, 666-678
CrossRef35
Keith C. Ferdinand. (2006) The Isosorbide-Hydralazine Story: Is There a Case for Race-Based Cardiovascular Medicine?. The Journal of Clinical Hypertension 8:3, 156-158
CrossRef36
Heart Failure Society of America. (2006) Section 15: Management of Heart Failure in Special Populations. Journal of Cardiac Failure 12:1, e115-e119
CrossRef37
David S. Jones, Roy H. Perlis. (2006) Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges. Harvard Review of Psychiatry 14:2, 92-108
CrossRef38
John Lynch, Tasha Dubriwny. (2006) Drugs and Double Binds: Racial Identification and Pharmacogenomics in a System of Binary Race Logic. Health Communication 19:1, 61-73
CrossRef39
Anne L. Taylor. (2005) The African American Heart Failure Trial: A Clinical Trial Update. The American Journal of Cardiology 96:7, 44-48
CrossRef40
Clyde W. Yancy. (2005) Heart Failure in African Americans. The American Journal of Cardiology 96:7, 3-12
CrossRef41
Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
CrossRef42
John V Terrovitis, Maria I Anastasiou-Nana, John N Nanas. (2005) Out-patient management of chronic heart failure. Expert Opinion on Pharmacotherapy 6:11, 1857-1881
CrossRef43
Crystal A. Gadegbeku, Janice P. Lea, Kenneth A. Jamerson. (2005) Update on Disparities in the Pathophysiology and Management of Hypertension: Focus on African Americans. Medical Clinics of North America 89:5, 921-933
CrossRef44
Sandeep A. Kamath, Clyde W. Yancy. (2005) Treatment of the african-american patient with congestive heart failure. Current Treatment Options in Cardiovascular Medicine 7:4, 307-315
CrossRef45
Shawna D. Nesbitt. (2005) Hypertension in black patients: Special issues and considerations. Current Hypertension Reports 7:4, 244-248
CrossRef46
Jalal K. Ghali. (2005) Beta-blockers in selected heart failure populations. Current Heart Failure Reports 2:2, 100-105
CrossRef47
Thomas W. Wallace, Mark H. Drazner. (2005) The impact of race on response to RAAS inhibition. Current Heart Failure Reports 2:2, 72-77
CrossRef48
(2005) Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine 352:10, 1041-1043
Full Text49
Abdallah S. Daar, Peter A. Singer. (2005) Opinion: Pharmacogenetics and geographical ancestry: implications for drug development and global health. Nature Reviews Genetics 6:3, 241-246
CrossRef50
Leslie C. Hussey, Sonya Hardin. (2005) Comparison of Characteristics of Heart Failure by Race and Gender. Dimensions of Critical Care Nursing 24:1, 41-46
CrossRef51
Sarah J Goodlin. (2005) Heart failure in the elderly. Expert Review of Cardiovascular Therapy 3:1, 99-106
CrossRef52
Michael A. Acker. (2004) Surgical therapies for heart failure. Journal of Cardiac Failure 10:6, S220-S224
CrossRef53
Taylor, Anne L., Ziesche, Susan, Yancy, Clyde, Carson, Peter, D'Agostino, Ralph Jr., Ferdinand, Keith, Taylor, Malcolm, Adams, Kirkwood, Sabolinski, Michael, Worcel, Manuel, Cohn, Jay N., . (2004) Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. New England Journal of Medicine 351:20, 2049-2057
Full Text54
Shawna D. Nesbitt. (2004) Hypertension in black patients: Special issues and considerations. Current Cardiology Reports 6:6, 416-420
CrossRef55
BENJAMIN R. BATES, KRISTAN POIROT, TINA M. HARRIS, CELESTE M. CONDIT, PAUL J. ACHTER. (2004) Evaluating Direct-to-Consumer Marketing of Race-Based Pharmacogenomics: A Focus Group Study of Public Understandings of Applied Genomic Medication. Journal of Health Communication 9:6, 541-559
CrossRef56
Clyde W. Yancy. (2004) The prevention of heart failure in minority communities and discrepancies in health care delivery systems. Medical Clinics of North America 88:5, 1347-1368
CrossRef57
Anne L. Taylor. (2004) Endothelial Dysfunction and Nitric Oxide Enhancing Therapy: A New Approach to the Treatment of Heart Failure. Congestive Heart Failure 10:5, 237-242
CrossRef58
Andrew Smart, Paul Martin, Michael Parker. (2004) Tailored Medicine: Whom Will it Fit? The Ethics of Patient and Disease Stratification. Bioethics 18:4, 322-343
CrossRef59
David E Lanfear, Sharon Marsh, Sharon Cresci, John A Spertus, Howard L McLeod. (2004) Frequency of compound genotypes associated with β-blocker efficacy in congestive heart failure. Pharmacogenomics 5:5, 553-558
CrossRef60
Jean-Bernard Durand. (2004) Heart Failure Management in African Americans: Meeting the Challenge. The Journal of Clinical Hypertension 6:s4, 42-47
CrossRef61
Clyde W. Yancy. (2004) Improving Outcomes in the Post-Myocardial Infarction Setting. The Journal of Clinical Hypertension 6:s4, 34-41
CrossRef62
Domenic Sica. (2004) Hypertension and End-Organ Disease in African Americans: Case Presentations. The Journal of Clinical Hypertension 6:s4, 48-53
CrossRef63
Clyde W Yancy, Domenic Sica. (2004) Cardiovascular Disease in African Americans. The Journal of Clinical Hypertension 6:s4, 54-56
CrossRef64
Stevo Julius, Michael H Alderman, Gareth Beevers, Björn Dahlöf, Richard B Devereux, Janice G Douglas, Jonathan M Edelman, Katherine E Harris, Sverre E Kjeldsen, Shawna Nesbitt, Otelio S Randall, Jackson T Wright. (2004) Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy. Journal of the American College of Cardiology 43:6, 1047-1055
CrossRef65
Jonathan D. Sackner-Bernstein, Hal A. Skopicki. (2004) Racing away from bias* *Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 43:5, 785-786
CrossRef66
Jianyi Zhang, Jagat Narula. (2004) Molecular biology of myocardial recovery. Surgical Clinics of North America 84:1, 223-242
CrossRef67
Clyde W. Yancy, Sonjay Laskar, Eric Erichhom. (2004) The Use of Beta-Adrenergic Receptor Antagonists in the Treatment of African Americans With Heart Failure. Congestive Heart Failure 10:1, 34-37
CrossRef68
Arthur M Feldman. (2003) The emerging role of pharmacogenomics in the treatment of patients with heart failure. The Annals of Thoracic Surgery 76:6, S2246-S2253
CrossRef69
Wendy M. Book, Brenda J. Hott. (2003) Beta-adrenergic receptor blockers in heart failure. Current Treatment Options in Cardiovascular Medicine 5:6, 475-485
CrossRef70
G NUNEZ. (2003) Culture, demographics, and critical care issues: an overview. Critical Care Clinics 19:4, 619-639
CrossRef71
Bernhard R Winkelmann. (2003) Pharmacogenomics, genetic testing and ethnic variability: tackling the ethical questions. Pharmacogenomics 4:5, 531-535
CrossRef72
William E. Chavey, Barry E. Bleske, John M. Nicklas. (2003) Controversies in the Use of Beta Blockers in Heart Failure. Congestive Heart Failure 9:5, 255-262
CrossRef73
Georges Chahoud, Jacob Joseph. (2003) Beta-blockade in chronic heart failure: does it work in everyone?. Current Opinion in Cardiology 18:5, 400-405
CrossRef74
Rick A. Kittles, Kenneth M. Weiss. (2003) R
ACE , ANCESTRY ,AND GENES : Implications for Defining Disease Risk. Annual Review of Genomics and Human Genetics 4:1, 33-67
CrossRef75
Robert E. Taylor. (2003) Pharmacological and Cultural Considerations in Alcohol Treatment Clinical Trials: Issues in Clinical Research Related to Race and Ethnicity. Alcoholism: Clinical & Experimental Research 27:8, 1345-1348
CrossRef76
Robert L. Scott. (2003) Is Heart Failure in African Americans a Distinct Entity?. Congestive Heart Failure 9:4, 193-196
CrossRef77
Benjamin M. Schaefer, Vincent Caracciolo, William H. Frishman, Pamela Charney. (2003) Gender, Ethnicity, and Genes in Cardiovascular Disease.. Heart Disease 5:3, 202-214
CrossRef78
Susan K. Maue, James H. Jackson, Bruce A. Weiss, Marc L. Rivo, Vishu Jhaveri, Barbara Lennert. (2003) The Hypertension Management Program: Identifying Opportunities for Improvement. The Journal of Clinical Hypertension 5:3, 33-40
CrossRef79
Paul G. Shekelle, Michael W. Rich, Sally C. Morton, Col.Sid W. Atkinson, Wenli Tu, Margaret Maglione, Shannon Rhodes, Michael Barrett, Gregg C. Fonarow, Barry Greenberg, Paul A. Heidenreich, Tom Knabel, Marvin A. Konstam, Anthony Steimle, Lynne Warner Stevenson. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology 41:9, 1529-1538
CrossRef80
Ori Ben-Yehuda. (2003) Hypertension, angiotensin II, aldosterone, and race**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 41:7, 1156-1158
CrossRef81
John G.F Cleland. (2003) β-Blockers for heart failure: why, which, when, and where. Medical Clinics of North America 87:2, 339-371
CrossRef82
Ragavendra R Baliga, Jagat Narula. (2003) Pharmacogenomics of congestive heart failure. Medical Clinics of North America 87:2, 569-578
CrossRef83
Sean O. Henderson, Philip Bretsky, Vincent DeQuattro, Brian E. Henderson. (2003) Treatment of Hypertension in African Americans and Latinos: The Effect of JNC VI on Urban Prescribing Practices. The Journal of Clinical Hypertension 5:2, 107-112
CrossRef84
Jackson T. Wright, Janice Douglas. (2003) Optimal Treatment of Hypertension and Cardiovascular Risk Reduction in African Americans: Treatment Approaches for Outpatients. The Journal of Clinical Hypertension 5:1, 18-25
CrossRef85
Gillian M Keating, Blair Jarvis. (2003) Carvedilol. Drugs 63:16, 1697-1741
CrossRef86
Sandra Soo-Jin Lee. (2003) Race, Distributive Justice and the Promise of Pharmacogenomics. American Journal of PharmacoGenomics 3:6, 385-392
CrossRef87
Ravi K. Garg, A. Nasser Khan, Allen S. Anderson. (2002) Contemporary use of beta receptor antagonists in chronic heart failure. Comprehensive Therapy 28:4, 207-213
CrossRef88
P.- G. Chassot, A. Delabays, D. R. Spahn. (2002) Preoperative evaluation of patients with, or at risk of, coronary artery disease undergoing non-cardiac surgery. British Journal of Anaesthesia 89:5, 747-759
CrossRef89
Eugene S. Smith, Suzanne Trussell, Laura J. Mencer. (2002) Prevention of heart failure. Current Opinion in Cardiology 17:5, 512-517
CrossRef90
Emelia J Benjamin, Sidney C Smith, Richard S Cooper, Martha N Hill, Russell V Luepker. (2002) Task Force #1—magnitude of the prevention problem: opportunities and challenges. Journal of the American College of Cardiology 40:4, 588-603
CrossRef91
Keith C. Ferdinand, Claudia C. Serrano, Daphne P. Ferdinand. (2002) Contemporary treatment of heart failure: Is there adequate evidence to support a unique strategy for African-Americans? con position. Current Hypertension Reports 4:4, 311-318
CrossRef92
A. M. Pritchett, M. M. Redfield. (2002) -Blockers: New Standard Therapy for Heart Failure. Mayo Clinic Proceedings 77:8, 839-846
CrossRef93
Daniel L Dries, Mark H Strong, Richard S Cooper, Mark H Drazner. (2002) Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. Journal of the American College of Cardiology 40:2, 311-317
CrossRef94
Harold L Kennedy, Robert S Rosenson. (2002) Physicians’ interpretation of “class effects”. Journal of the American College of Cardiology 40:1, 19-26
CrossRef95
Clyde W. Yancy. (2002) The role of race in heart failure therapy. Current Cardiology Reports 4:3, 218-225
CrossRef96
David Zeltsman, Michael A. Acker. (2002) S
URGICAL MANAGEMENT OF HEART FAILURE : An Overview. Annual Review of Medicine 53:1, 383-391
CrossRef97
Andrew Owen. (2002) Optimising the Use of ??-Blockers in Older Patients with Heart Failure. Drugs & Aging 19:9, 671-684
CrossRef98
William L. Lombardi, Edward M. Gilbert. (2001) Carvedilol in the failing heart. Clinical Cardiology 24:12, 757-766
CrossRef99
McNeil, Barbara J., . (2001) Hidden Barriers to Improvement in the Quality of Care. New England Journal of Medicine 345:22, 1612-1620
Full Text100
(2001) Race and Responsiveness to Drugs for Heart Failure. New England Journal of Medicine 345:10, 766-768
Full Text101
Braunwald, Eugene, . (2001) Expanding Indications for Beta-Blockers in Heart Failure. New England Journal of Medicine 344:22, 1711-1712
Full Text102
Schwartz, Robert S., . (2001) Racial Profiling in Medical Research. New England Journal of Medicine 344:18, 1392-1393
Full Text103
Wood, Alastair J.J., . (2001) Racial Differences in the Response to Drugs — Pointers to Genetic Differences. New England Journal of Medicine 344:18, 1394-1396
Full Text
